Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. - Wikidata - awgldk - TriplyDB

Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels.

Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels.

http://www.wikidata.org/entity/Q34241186

about

From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseases Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease.PCSK9 and Atherosclerosis - Lipids and Beyond.Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke.Local effects of human PCSK9 on the atherosclerotic lesion.Effects of LDL Receptor Modulation on Lymphatic Function Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.Proprotein convertase subtilisin/kexin type 9 expression is transiently up-regulated in the acute period of myocardial infarction in rat.Hemodynamic shear stress via ROS modulates PCSK9 expression in human vascular endothelial and smooth muscle cells and along the mouse aorta.IDOL N342S Variant, Atherosclerosis Progression and Cardiovascular Disorders in the Italian General Population.PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE.Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study.Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Its Inhibitors: a Review of Physiology, Biology, and Clinical Data.Nature and nurture in atherosclerosis: The roles of acylcarnitine and cell membrane-fatty acid intermediates.Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line.Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16 randomized controlled treatment arms Plasma Levels of Proprotein Convertase Subtilisin/Kexin Type 9 Are Elevated in Patients With Peripheral Artery Disease and Associated With Metabolic Disorders and Dysfunction in Circulating Progenitor Cells.Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease Epidermal growth factor receptor plays a role in the regulation of liver and plasma lipid levels in adult male mice PCSK9 targets important for lipid metabolism Inhibition of pro-protein convertase subtilisin kexin 9 [corrected] (PCSK-9) as a treatment for hyperlipidaemia.Anti-PCSK9 therapies for the treatment of hypercholesterolemia.PCSK9 Inhibitors: potential in cardiovascular therapeutics.Proprotein convertases subtilisin/kexin type 9, an enzyme turned escort protein: hepatic and extra hepatic functions.Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9.Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials.PCSK9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease.Effect of E670G Polymorphism in PCSK9 Gene on the Risk and Severity of Coronary Heart Disease and Ischemic Stroke in a Tunisian Cohort.Cross-talk between LOX-1 and PCSK9 in vascular tissues.High circulating proprotein convertase subtilisin/Kexin type 9 concentration associates with cardiovascular risk: A meta-analysis of cohort studies.Proprotein Convertase Subtilisin/Kexin 9 Levels in Relation to Systemic Immune Activation and Subclinical Coronary Plaque in HIV.PCSK9 induces a pro-inflammatory response in macrophages.Praluent (Alirocumab)-Induced Renal Injury.Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies.Serum PCSK9 is modified by interleukin-6 receptor antagonism in patients with hypercholesterolaemia following non-ST-elevation myocardial infarction

P2860

Q26741078-C668BF4E-0ED9-442A-A68D-C4C75CE1E05B Q27009477-46958F7D-0492-4A56-B0BA-91DDE18B4834 Q33599961-8C845D16-76B7-4D4C-A759-EC652AE2E8A1 Q33675963-E16EA2F5-D78B-491B-8E53-A48EBA585142 Q34479132-1EA8AD26-A20E-4C3F-8419-B35AAB1BD792 Q34492178-F0C2D53F-FE78-46FA-BEAD-6F12C20FDAC6 Q34530204-4EF895D5-C8BA-49D1-8D6B-7F504EFBA044 Q34536594-DA5C6DB8-D271-4F2E-84DF-25978D1065BF Q34789111-4B56EC94-E79C-4A76-9096-AEFC776D8D2F Q35181070-7A61B2A3-D4E6-46A2-8E5E-C7FA2F3D94AD Q35557701-F2ACB260-CEE2-4690-A09B-D0599BFBC2BA Q36196833-9B8C2E76-8609-458A-85F3-AC0A93556B1E Q36362512-AE32E256-89B9-4EFA-B7F4-6F66D2310BFE Q36411986-131AB14B-05DC-48DD-8DE0-8C9A3CEBDAF9 Q36418591-74E9AB1E-0283-4E99-A95F-0C8E06A629B4 Q36574008-4D0E8882-4F90-44AA-B1E8-F99D6DE40762 Q36924697-F400D4E1-7953-4E70-BF5B-7ECF46715F7B Q36956822-E87203A2-0D2D-44C3-9C61-DA7564C0CFA9 Q37278608-4BE94195-231B-442A-A691-369A1CD9A733 Q37629138-04B230B2-A512-42E0-9D78-38F102AC555B Q37703261-CB35801B-1487-4CB6-8BB0-EB9A5AD300CF Q38001736-389143FA-696D-4BB7-8132-6C369D2C9402 Q38067460-9A7359AE-8AFC-4C62-9B92-1B79A4CE3B81 Q38075818-F0B4DAD3-E27F-49CB-BFCC-2081A218DB6D Q38109960-53855E73-A296-45D9-9315-8D8A9F2367A1 Q38221015-1BCC6BC6-0C2B-408B-A862-2A4400A59AB8 Q38424373-A3D75C36-915A-4E0A-A5C9-9C935959B5F7 Q38548750-1A798881-7123-4235-9265-44C1CCB75E1D Q39453691-7F8D3FED-5D2C-4A1A-A6C7-2673BEB7B043 Q39470591-781E3540-F52C-464C-9AD6-F567B6499A31 Q46712626-B0993DC8-E4F3-4066-A835-F6E7F9A72DF3 Q47139387-426F7783-36CE-449B-B042-B348DC2D6584 Q47143670-813E1015-3662-4F9B-AE9B-4244D4C864E5 Q48112725-8DCA0553-C029-46E0-9526-CCC6C28248EB Q51187390-C1244055-802F-4C6B-A669-C9D01FF5E281 Q51737068-227C0BFE-06D8-4212-B00A-AA7AAA5B972A Q58724610-BEA2C550-0EDD-4FAE-9CAF-57FCC575C56B

P2860

Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels.

http://www.wikidata.org/entity/Q34241186

description

2011 nî lūn-bûn

@nan

2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Proprotein convertase subtilis ...... duces macrophages LDLR levels.

@ast

Proprotein convertase subtilis ...... duces macrophages LDLR levels.

@en

Proprotein convertase subtilisin kexin type 9

@nl

type

label

Proprotein convertase subtilis ...... duces macrophages LDLR levels.

@ast

Proprotein convertase subtilis ...... duces macrophages LDLR levels.

@en

Proprotein convertase subtilisin kexin type 9

@nl

prefLabel

Proprotein convertase subtilis ...... duces macrophages LDLR levels.

@ast

Proprotein convertase subtilis ...... duces macrophages LDLR levels.

@en

Proprotein convertase subtilisin kexin type 9

@nl

P1433

Q34241186-4B1572B1-41EF-4A12-AB5D-3628E2D788AD

P1476

Q34241186-AB2968BD-3383-4B0E-9C57-DA6C9D53367E

P2093

Q34241186-0AF476B9-3978-497E-967F-C3F9AE624066

Q34241186-1311EF00-03ED-4FBD-9F99-DB4138A8FE52

Q34241186-21277F57-35C7-471C-A683-9912A7B31173

Q34241186-8DABD292-7657-45C8-AC25-2A0FF7F01F5A

Q34241186-BD8ACC88-24EE-478F-97BB-3A4A83469157

Q34241186-CD847AAF-A0AF-4C39-A61A-38C09380EA39

Q34241186-D1EFAE3B-C94C-45A9-98EE-7E95375D8F60

Q34241186-EF33EFD3-4434-4667-AFE9-A49D735B9311

P304

Q34241186-BFDD7E7D-CD79-4DF8-9B14-4444E6126001

P31

Q34241186-2A5F99F1-A336-4471-BD38-1199FAD35ABF

P356

Q34241186-6E9A98A7-62F0-4220-A061-CA51D5972AF0

P433

Q34241186-0FC202AE-205C-4539-BFCE-BDCBE3E4B6DA

P478

Q34241186-A626615F-2EA9-4E69-8F5D-B56DE540425C

P577

Q34241186-937A18E2-CF67-461B-871D-C0F573548049

P5875

Q34241186-6F96F17F-C029-4F75-9E14-7BE78796F957

P698

Q34241186-17DB9545-EBCA-441D-97A0-174AB81E4F5E

P921

Q34241186-1FA40EF3-7FF8-4015-B6BE-8ED014815617

P356

J.ATHEROSCLEROSIS.2011.11.026

P1433

Atherosclerosis

P1476

Proprotein convertase subtilis ...... duces macrophages LDLR levels.

@en

P2093

Alberico Luigi Catapano

http://www.w3.org/2001/XMLSchema#string

Alberto Corsini

http://www.w3.org/2001/XMLSchema#string

Andrea Mezzetti

http://www.w3.org/2001/XMLSchema#string

Angela Pirillo

http://www.w3.org/2001/XMLSchema#string

Francesco Cipollone

http://www.w3.org/2001/XMLSchema#string

Gianpaolo Tibolla

http://www.w3.org/2001/XMLSchema#string

Nicola Ferri

http://www.w3.org/2001/XMLSchema#string

Stefano Pacia

http://www.w3.org/2001/XMLSchema#string

P304

381-386

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.ATHEROSCLEROSIS.2011.11.026

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

220

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51886302

http://www.w3.org/2001/XMLSchema#string

P698

22176652

http://www.w3.org/2001/XMLSchema#string

P921